Charles River Labs stock gains after rapid cell banking launch

Published on 09/20/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Charles River Labs stock most recently closed at USD 281.67 on September 18, 2026, near one fair value estimate of USD 282 from recent analysis. The shares have delivered a 79.42 percent one-year total return, underpinned by demand for rapid cell banking services.

Moderner CRO-Forschungscampus mit Glasfassade in Wilmington Massachusetts — Charles River Laboratories Forschungscampus in Wilmington Massachusetts, modernes Glaslaborgebäude, ISIN US1591881009, Außenansicht, Illustration mit AI erstellt.

Charles River Laboratories International Inc. stock (ISIN US1591881009) most recently closed at 281.67 USD on its primary US listing as of September 18, 2026, a level that sits almost exactly in line with one fair value estimate of about 282 USD from recent analysis and reflects the market response to its rapid cell banking launch, according to Ad-hoc-news.

Stock performance and valuation context

As of September 18, 2026, Charles River Laboratories International stock has delivered a 90-day share price gain of 52.25 percent, highlighting how strongly the market has repriced the company in a relatively short period, according to recent analysis cited by Ad-hoc-news.

Over a longer horizon, the same overview notes that the company has generated a 79.42 percent one-year total shareholder return as of September 18, 2026, underscoring that the recent rally comes on top of already strong gains for long-term holders rather than from a depressed base, according to Ad-hoc-news.

Rapid cell banking launch as current driver

The current narrative around Charles River Labs stock is closely tied to its rapid cell banking offering, which has been highlighted as a key catalyst for recent share price strength because it aims to accelerate the preparation and storage of cell lines for biopharmaceutical customers, a capability that can help shorten development timelines, according to the coverage by Ad-hoc-news.

From a valuation perspective, the same analysis indicates that the recent close of 281.67 USD on September 18, 2026, is broadly consistent with a fair value estimate of around 282 USD, suggesting that while the rapid cell banking launch has supported sentiment, the shares are not priced far above modeled intrinsic value in that particular view, according to Ad-hoc-news.

Investor takeaway and market context

For investors, the combination of a 52.25 percent gain over the past 90 days and a 79.42 percent one-year total shareholder return as of September 18, 2026, means that Charles River Labs stock is now trading much higher than it was a year ago, which in turn raises the importance of monitoring whether operational catalysts such as rapid cell banking can translate into sustained earnings and cash flow growth over the coming quarters, as emphasized by Ad-hoc-news.

The near alignment between the 281.67 USD closing price on September 18, 2026, and the roughly 282 USD fair value estimate cited in that analysis also suggests that, at least in this framework, most of the upside from the rapid cell banking story may already be reflected in the share price, putting more weight on future data points such as upcoming quarterly results or additional service launches to shift the valuation narrative meaningfully, according to Ad-hoc-news.

Stock level as of the last close

Based on the latest available data, Charles River Labs stock most recently closed at 281.67 USD on its primary US listing as of September 18, 2026, in United States dollars, a price point that reflects both the strong recent momentum and the market's current assessment of the company's prospects in areas such as rapid cell banking and broader laboratory services.